Legal & General Group PLC Protagonist Therapeutics, Inc Transaction History

Legal & General Group PLC

$390 Billion
Q2 2025

A detailed history of Legal & General Group PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Legal & General Group PLC holds 166,181 shares of PTGX stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,181

Previous 148,107 12.2%

Holding current value

$12.9 Million

Previous $7.16 Million 28.23%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$40.89 - $56.37 $739,045 - $1.02 Million	18,074 Added 12.2%	166,181 $9.18 Million
Q1 2025 May 15, 2025	SELL	$35.09 - $59.76 $156,325 - $266,230	-4,455 Reduced 2.92%	148,107 $7.16 Million
Q4 2024 Feb 13, 2025	SELL	$38.51 - $48.43 $186,850 - $234,982	-4,852 Reduced 3.08%	152,562 $5.89 Million
Q3 2024 Feb 28, 2025	BUY	$33.72 - $47.33 $14,971 - $21,014	444 Added 0.29%	153,006 $6.88 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $3.3 Million - $4.63 Million	97,877 Added 164.4%	157,414 $7.07 Million
Q2 2024 May 29, 2025	BUY	$24.66 - $34.8 $64,116 - $90,479	2,600 Added 5.13%	53,286 $1.85 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $218,265 - $308,014	8,851 Added 17.46%	59,537 $2.06 Million
Q1 2024 May 29, 2025	SELL	$21.79 - $32.15 $2.12 Million - $3.13 Million	-97,421 Reduced 65.78%	50,686 $1.47 Million
Q1 2024 Jul 01, 2024	BUY	$21.79 - $32.15 $67,679 - $99,857	3,106 Added 6.53%	50,686 $1.47 Million
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $49,920 - $73,655	2,291 Added 5.06%	47,580 $1.38 Million
Q4 2023 May 29, 2025	SELL	$14.05 - $23.44 $1.44 Million - $2.41 Million	-102,818 Reduced 69.42%	45,289 $1.04 Million
Q4 2023 Feb 15, 2024	BUY	$14.05 - $23.44 $7,362 - $12,282	524 Added 1.17%	45,289 $1.04 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $4,420 - $6,269	265 Added 0.6%	44,765 $746,000
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $457,059 - $744,687	25,364 Added 132.55%	44,500 $1.23 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $50,967 - $119,996	4,728 Added 32.82%	19,136 $440,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $8,228 - $12,488	1,118 Added 8.41%	14,408 $157,000
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $38,010 - $56,629	-4,836 Reduced 26.68%	13,290 $112,000
Q2 2022 Aug 22, 2022	SELL	$7.06 - $25.52 $24,484 - $88,503	-3,468 Reduced 16.06%	18,126 $143,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $7,702 - $11,906	330 Added 1.55%	21,594 $511,000
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $11,142 - $23,447	632 Added 3.06%	21,264 $727,000
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $104,519 - $401,047	8,071 Added 64.25%	20,632 $365,000
Q2 2021 Aug 12, 2021	BUY	$25.57 - $44.88 $51,549 - $90,478	2,016 Added 19.12%	12,561 $563,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $4,431 - $7,257	233 Added 2.26%	10,545 $273,000
Q4 2020 Feb 12, 2021	BUY	$18.49 - $25.13 $123,809 - $168,270	6,696 Added 185.18%	10,312 $208,000
Q3 2020 Nov 13, 2020	SELL	$15.19 - $22.4 $1,610 - $2,374	-106 Reduced 2.85%	3,616 $71,000
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $6,394 - $19,461	1,033 Added 38.42%	3,722 $66,000
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $4,438 - $7,578	-822 Reduced 23.41%	2,689 $19,000
Q4 2019 Feb 13, 2020	BUY	$4.69 - $13.45 $1,997 - $5,729	426 Added 13.81%	3,511 $25,000
Q3 2019 Nov 13, 2019	BUY	$9.41 - $16.56 $5,222 - $9,190	555 Added 21.94%	3,085 $37,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $22,719 - $32,788	2,530 New	2,530 $31,000
Q2 2018 Aug 10, 2018	SELL	$5.99 - $9.1 $13,207 - $20,065	-2,205 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$14.47 - $20.8 $31,906 - $45,864	2,205	2,205 $46,000

Others Institutions Holding PTGX

# of Institutions

297

Shares Held

67.4M

Call Options Held

290K

Put Options Held

318K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $3.81B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Protagonist Therapeutics, Inc Transaction History